stockrow
Friday 6 November 2026
Export SINT’s income statement to Excel — free account
SINTX TECHNOLOGIES, INC.
SINT Healthcare Medical Devices
SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024.
- Revenue
- +952.9%
- EPS
- +93.1%
- Free cash flow
- +47.4%
- Total debt
- −6.78%
Quarter to September 2026, against a year earlier
1.56
0.06
−3.70%
Follow SINT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.49 | 6.82 | 9.75 | 10.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.86) | (3.28) | (4.03) | (4.57) | |
P/B ratio |
4.39 | 1.88 | 11.10 | 3.66 | |
Price to Tangible BV |
5.02 | 2.06 | 21.40 | 4.31 | |
EV/Sales |
3.90 | 4.21 | 8.03 | 6.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.44) | (0.55) | (0.85) | (0.77) | |
EV/FCF |
(1.40) | (0.54) | (0.86) | (0.78) | |
Quick Ratio |
0.71 | 1.32 | 0.54 | 1.16 | |
Current Ratio |
1.84 | 2.36 | 1.04 | 1.51 | |
Net Debt/EBITDA |
0.00 | 1.28 | 0.58 | 1.92 | |
Debt/Assets |
0.62% | 0.98% | 1.36% | 0.07% | |
Debt/Equity |
0.02 | 0.02 | 0.12 | 0.00 | |
Asset Turnover |
0.33 | 0.14 | 0.11 | 0.11 | |
Operating CF/Net income |
0.00 | 0.76 | 0.88 | 1.06 | |
Capex/Depreciation |
— | (0.55) | (0.04) | (0.26) | |
Interest Coverage |
(817.50) | (1,444.00) | (267.25) | (193.17) | |
Research and Development Expense of Revenue |
25.02% | 126.77% | 95.79% | 334.14% | |
Selling, General and Administrative Expense of Revenue |
109.18% | 573.23% | 772.11% | 518.28% | |
Intangible Assets out of Total Assets |
0.00 | 0.04 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
13.74% | 78.10% | 139.47% | 224.48% | |
Graham Net Nets |
0.00 | 0.16 | (0.26) | (0.09) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(101.77%) | (293.55%) | (225.98%) | (161.64%) | |
Free Cash Flow Yield |
(62.15%) | (114.54%) | (95.59%) | (79.00%) | |
Revenue per Share |
0.33 | 0.09 | 0.09 | 0.10 | |
Operating CF per Share |
(0.21) | (0.57) | (0.62) | (0.85) | |
Capex per Share |
0.00 | (0.02) | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.21) | (0.59) | (0.62) | (0.86) | |
Cash per Share |
0.30 | 0.74 | 0.47 | 1.49 | |
Shareholders Equity per Share |
0.51 | 1.00 | 0.23 | 1.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.51 | 1.00 | 0.23 | 1.06 | |
Free Cash Flow |
(1.37) | (2.85) | (2.50) | (2.39) | |
Working Capital |
2.52 | 4.05 | 0.15 | 1.92 | |
Capital Expenditures |
— | (0.08) | (0.01) | (0.04) | |
Net Current Asset Value |
0.01 | 1.43 | (2.58) | (0.93) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.19 | 0.02 | 0.14 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.13 | 0.21 | 0.23 | 0.19 | |
Average Payables |
0.58 | 0.56 | 0.50 | 0.34 | |
Average Inventory |
1.50 | 1.30 | 0.91 | 0.66 | |
Average Assets |
10.13 | 9.81 | 9.63 | 9.46 | |
Average Common Equity |
3.73 | 4.41 | 3.50 | 3.41 |
Columns are period end dates · fundamentals updated 5 Nov 2026